查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1629905

全球醫藥冷鏈物流市場 - 2025-2033

Global Pharmaceutical Cold Chain Logistics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球醫藥冷鏈物流市場2024年達186億美元，預計2033年將達271億美元，2025-2033年預測期間複合年成長率為4.3%。

藥品冷鏈物流是指在整個供應鏈中管理、儲存和運輸對溫度敏感的藥品（例如疫苗、生物製品和其他需要嚴格溫度控制以保持其有效性和安全性的醫藥產品）的專門過程。藥品冷鏈物流涉及對溫度敏感的藥品從製造到最終交付給最終用戶的整個生命週期的管理。此物流系統包括溫控儲存、運輸、包裝、即時監控和追蹤。

過去十年，醫藥冷鏈物流經歷了快速創新與發展。對生物製品和其他溫度敏感藥物的需求不斷成長，增加了對可靠的溫控分配系統的需求。例如，根據美國國立衛生研究院的數據，近年來，生物製劑佔核准藥物總量的比例不足30%。 2000 年代初，在行業專家共同努力提高認知和標準化最佳實踐的推動下，出現了對冷鏈物流的專門關注。

市場動態：

驅動程式和限制

冷鏈技術不斷進步

冷鏈技術的不斷進步極大地推動了藥品冷鏈物流市場的成長，預計將在預測期內推動該市場的發展。支援物聯網的解決方案透過即時監控運輸和儲存過程中的環境條件，徹底改變了冷鏈物流。這些系統使用感測器持續追蹤溫度、濕度和其他條件，提醒物流提供者任何偏差。這確保了藥品的完整性，特別是對溫度變化敏感的疫苗和生物製劑。

例如，2024 年 2 月，Sensitech 推出了 TempTale GEO X，這是一款專為生命科學產業和物流組織量身定做的創新物聯網溫度監測解決方案。這項尖端解決方案旨在為全球透過航空、海運、公路和鐵路等各種運輸方式運輸的溫度敏感藥物和疫苗提供即時監控和分析。 TempTale GEO X 代表在增強藥品供應鏈冷鏈合規性、供應鏈效率和永續性成果方面向前邁出了重要一步。

此外，2022 年 9 月，新創公司 CubeWorks 透過突破性的智慧感測解決方案加速物聯網的未來，推出了新一代冷鏈物流視覺化解決方案 CubiSens XT1。 XT1 是同類中首款溫度追蹤器，能夠對生物製藥產品進行產品級監控，以確保整個生命週期的溫度合規性和品質保證。 CubiSens XT1 的直徑僅 16 毫米，比傳統資料記錄儀小 100 倍，足夠小，足以安裝在任何需要溫度監控的單一產品上。

自動化系統正在整合到冷鏈物流中，用於分類、處理和儲存對溫度敏感的藥品。這些技術降低了人為錯誤的風險，提高了效率，並改善了 GDP 法規的合規性。例如，2024 年 6 月，主動供應鏈風險管理和情報領域的全球領導者 Overhaul 推出了其尖端的冷鏈品質解決方案。這項創新的軟體解決方案為時間和溫度敏感的貨物提供無與倫比的風險和品質管理，確保製藥、醫療保健和高價值食品和飲料行業的整個供應鏈處於最佳狀態。

監管挑戰

監理挑戰是醫藥冷鏈物流市場成長的重大障礙。良好分銷規範 (GDP) 和良好製造規範 (GMP) 等嚴格法規要求高水準的合規性，其中包括在儲存和運輸過程中保持適當的溫度控制。由於需要專門的設備、設施和人員，這些標準的實施和維護成本高昂。

例如，FDA 的 GDP 指南要求對藥品的溫控運輸進行嚴格的記錄和監控。遵守這些準則需要對技術和基礎設施進行大量投資，這可能對小型物流提供者構成障礙。

不同地區有不同的監管要求。在美國，FDA 主要透過良好分銷規範 (GDP) 和現行良好生產規範 (cGMP) 提供全面的冷鏈管理指南。這些法規確保藥品在適當的條件下儲存、處理和運輸，以維持其安全性、有效性和品質。歐洲藥品管理局 (EMA) 對歐盟境內的藥品分銷制定了嚴格的冷鏈要求。這種不一致使物流管理變得複雜，尤其是對於全球營運而言。

監管機構會對不合規的公司處以巨額罰款和製裁，例如溫度超出範圍會損壞藥品。這些處罰可能很嚴厲，導致經濟損失和聲譽受損。例如，由於溫度處理不當而導致的產品召回可能會給公司帶來數百萬美元的銷售損失、法律費用以及品牌聲譽受損。

目錄

第1章：市場介紹和範圍

  • 報告的目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類的片段
  • 按服務類型分類的片段
  • 按溫度範圍分類的片段
  • 按交付方式分類的片段
  • 最終使用者的片段
  • 按地區分類的片段

第 3 章：動力學

  • 影響因素
    • 促進要素
      • 冷鏈技術不斷進步
      • 虛擬控制塔和即時追蹤
    • 限制
      • 監管挑戰
    • 機會
    • 影響分析

第 4 章：策略洞察與產業展望

  • 市場領導者和先驅
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的知名領導者
    • 擁有成熟產品的市場領導者
  • 新興新創企業和關鍵創新者
  • CXO 觀點
  • 最新進展和突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：藥品冷鏈物流市場，依產品類型

  • 疫苗
  • 生物製藥
  • 藥品和藥品

第 6 章：藥品冷鏈物流市場（依服務類型）

  • 貯存
  • 運輸
  • 包裝
  • 其他

第 7 章：藥品冷鏈物流市場（依溫度範圍）

  • 冷凍（-20°C以下）
  • 冷藏（2°C 至 8°C）
  • 環境溫度（15°C 至 25°C）
  • 低溫（-150°C）

第 8 章：藥品冷鏈物流市場（以交付方式）

  • 最後一哩交付
  • 集線器到經銷商

第 9 章：藥品冷鏈物流市場（依最終用戶）

  • 製藥和生物製藥公司
  • 生技公司
  • 醫院和醫療機構
  • 其他

第 10 章：醫藥冷鏈物流市場，按區域市場分析與成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的主要發展
  • 公司基準化分析

第 12 章：公司簡介

  • Cardinal Health
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
    • SWOT分析
  • AmerisourceBergen Corporation
  • Envirotainer AB
  • FedEx
  • United Parcel Service of America, Inc.
  • Thermo King
  • Sonoco ThermoSafe
  • B Medical Systems India Private Limited
  • DoKaSch TEMPERATURE SOLUTIONS GmbH
  • Nordic Cold Chain Solutions

第 13 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 14 章：附錄

簡介目錄
Product Code: PH8935

The global pharmaceutical cold chain logistics market reached US$ 18.6 billion in 2024 and is expected to reach US$ 27.1 billion by 2033, growing at a CAGR of 4.3% during the forecast period 2025-2033.

Pharmaceutical cold chain logistics refers to the specialized process of managing, storing and transporting temperature-sensitive pharmaceutical products such as vaccines, biologics and other medicinal products that require strict temperature controls to maintain their efficacy and safety throughout the supply chain. Pharmaceutical cold chain logistics involves the management of the entire lifecycle of temperature-sensitive pharmaceutical products from manufacturing through to the final delivery to the end-user. This logistics system includes temperature-controlled storage, transportation, packaging, real-time monitoring and tracking.

In the past decade, pharmaceutical cold chain logistics has experienced rapid innovation and growth. The increasing demand for biologics and other temperature-sensitive medicines has heightened the need for reliable, temperature-controlled distribution systems. For instance, according to the National Institute of Health, in recent years, biologics have accounted for less than 30% of the total drugs approved. In the early 2000s, a specialized focus on cold chain logistics emerged, driven by a collaborative effort among industry experts to promote awareness and standardize best practices.

Market Dynamics: Drivers & Restraints

Rising advancements in cold chain technology

The rising advancements in cold chain technology are significantly driving the growth of the Pharmaceutical Cold Chain Logistics market and are expected to drive the market over the forecast period. IoT-enabled solutions have revolutionized cold chain logistics by providing real-time monitoring of environmental conditions during transport and storage. These systems use sensors to continuously track temperature, humidity, and other conditions, alerting logistics providers to any deviations. This ensures the integrity of pharmaceutical products, especially vaccines and biologics, which are sensitive to temperature changes.

For instance, in February 2024, Sensitech introduced TempTale GEO X, an innovative IoT temperature monitoring solution tailored specifically for the life sciences industry and logistics organizations. This cutting-edge solution is designed to deliver real-time monitoring and analytics for temperature-sensitive medicines and vaccines transported globally across various modes of transportation, including air, ocean, road, and rail. TempTale GEO X represents a significant step forward in enhancing cold chain compliance, supply chain efficiency, and sustainability outcomes in the pharmaceutical supply chain.

Additionally, in September 2022, CubeWorks, a startup company accelerating the future of IoT through breakthrough smart sensing solutions, introduced the next-generation visibility solution for cold chain logistics with the CubiSens XT1. The XT1 is the first temperature tracker of its kind that enables product-level monitoring of biopharma products for temperature compliance and quality assurance for the entire lifecycle. Measuring a mere 16 mm in diameter, the CubiSens XT1 is 100x smaller than conventional data loggers, small enough to fit on any individual product that requires temperature monitoring.

Automated systems are being integrated into cold chain logistics for sorting, handling, and storing temperature-sensitive pharmaceuticals. These technologies reduce the risk of human error, enhance efficiency, and improve compliance with GDP regulations. For instance, in June 2024, Overhaul, a global leader in active supply chain risk management and intelligence, launched its cutting-edge Cold Chain Quality Solution. This innovative software solution delivers unparalleled risk and quality management for time and temperature-sensitive cargo, ensuring optimal conditions throughout the supply chain for the pharmaceutical, healthcare and high-value food and beverage sectors.

Regulatory challenges

Regulatory challenges are a significant barrier to the growth of the pharmaceutical cold chain logistics market. Stringent regulations such as Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP) require high levels of compliance, which includes maintaining proper temperature controls during storage and transportation. These standards are expensive to implement and maintain due to the need for specialized equipment, facilities, and personnel.

For instance, the FDA's GDP guidelines mandate strict documentation and monitoring of temperature-controlled shipments for pharmaceuticals. Compliance with these guidelines requires significant investments in technology and infrastructure, which can be a barrier for smaller logistics providers.

Different regions have different regulatory requirements. In the United States, the FDA provides comprehensive guidelines for cold chain management, primarily through the Good Distribution Practices (GDP) and current Good Manufacturing Practices (cGMP). These regulations ensure that pharmaceutical products are stored, handled, and transported under appropriate conditions to maintain their safety, efficacy, and quality. The European Medicines Agency (EMA) sets out strict cold chain requirements for pharmaceutical distribution within the European Union. This inconsistency complicates logistics management, especially for global operations.

Regulatory bodies impose heavy fines and sanctions on companies for non-compliance, such as temperature excursions that damage pharmaceutical products. These penalties can be severe, leading to financial losses and reputational damage. For instance, a product recall due to temperature mishandling could cost a company millions in lost sales, legal fees, and damage to its brand reputation.

Segment Analysis

The global pharmaceutical cold chain logistics market is segmented based on product type, service type, temperature range, mode of delivery, end-user and region.

Temperature Range:

The cryogenic segment is expected to dominate the pharmaceutical cold chain logistics market share

The demand for Cryogenic conditions (temperatures typically below -150°C) is usually high as these are essential for transporting and storing advanced biopharmaceutical products such as mRNA vaccines, gene therapies and CAR-T cell therapies. These products are highly sensitive to temperature variations, necessitating ultra-low temperature logistics to maintain their stability and efficacy.

For instance, in April 2024, CSafe launched three new technologies building on its portfolio of solutions integrating real-time data tracking to ensure maximum visibility throughout the shipping journey. CSafe's Multi-Use Dewars, the first in the CGT Cryo Series, are designed to serve the growing cell and gene therapy market. These cryogenic, reusable dewars maintain the coldest temperature range of -150°C or colder. This technology uses liquid nitrogen dry vapor units and includes a built-in TracSafe RLT real-time data tracking device.

Technological advancements have made cryogenic logistics more efficient and reliable. The development of advanced cryogenic packaging solutions, including passive cooling technologies like phase change materials and insulated containers, has improved the ability to maintain ultra-low temperatures for longer periods, especially during transit.

Geographical Analysis

North America is expected to hold a significant position in the Pharmaceutical Cold Chain Logistics market share

North America, particularly the United States and Canada, boasts a highly developed healthcare system with a significant demand for biologics, vaccines and temperature-sensitive pharmaceuticals. The region's advanced cold chain infrastructure, including a vast network of refrigerated warehouses and transportation facilities, ensures that products remain stable from manufacturer to patient.

For instance, in six years, NewCold has gone from zero to three of the most advanced temperature-controlled warehouses in the United States, with a fourth set to become operational in mid-2024. January 18, 2024 marks six years since the first pallet was received in 2018. At the time of its founding, NewCold Tacoma was considered one of the most energy-efficient and technologically advanced North American automated warehouses in the United States.

North America leads globally in the demand for biopharmaceuticals such as vaccines, biologics, and advanced therapies. This demand drives the growth of the cold chain logistics market as these products require ultra-low temperatures during transit and storage. For instance, according to the National Institute of Health (NIH), U.S. vaccine sales are estimated to be about $1.5 billion per year.

North America is a hub for cold chain technology innovation. The region is at the forefront of developing advanced logistics technologies such as IoT-enabled real-time temperature monitoring, automated warehouses, and cryogenic packaging solutions. These advancements enhance the efficiency and reliability of cold chain logistics.

For instance, Sensitech introduced TempTale GEO X, an innovative IoT temperature monitoring solution tailored specifically for the life sciences industry and logistics organizations. This cutting-edge solution is designed to deliver real-time monitoring and analytics for temperature-sensitive medicines and vaccines transported globally across various modes of transportation, including air, ocean, road, and rail. TempTale GEO X represents a significant step forward in enhancing cold chain compliance, supply chain efficiency, and sustainability outcomes in the pharmaceutical supply chain.

Asia-Pacific is growing at the fastest pace in the Pharmaceutical Cold Chain Logistics market

The Asia-Pacific region is rapidly improving its cold chain logistics infrastructure, with investments in refrigerated warehouses, transportation networks, and technology upgrades such as real-time monitoring systems. Countries like China and India are particularly active in expanding their cold chain networks to support the growing demand for temperature-sensitive pharmaceuticals.

For instance, in October 2024, UPS launched its specialized healthcare-focused cross-docking facility in Hyderabad. The facility is designed as a pharma-grade facility and comes with global freight forwarding capabilities. Providing an additional layer of security for temperature-controlled pharmaceutical shipments, it can hold or sort 15 pallets at +15°C to +25°C, 7 Pallets at +2 to +8°C and 50 pallets under uncontrolled ambient conditions. This enables pharma companies to distribute their products more efficiently, eliminating the need for prolonged warehouse storage.

Competitive Landscape

The major global players in the pharmaceutical cold chain logistics market include Cardinal Health, AmerisourceBergen Corporation, Envirotainer AB, FedEx, United Parcel Service of America, Inc., Thermo King, Sonoco ThermoSafe, B Medical Systems India Private Limited, DoKaSch TEMPERATURE SOLUTIONS GmbH, Nordic Cold Chain Solutions and among others.

The Growth and Future of Pharmaceutical Cold Chain Logistics

  • The pharmaceutical cold chain market has experienced rapid growth over the past decade, often outpacing the pharmaceutical industry itself. Cold chain shipments have consistently grown at a rate double that of the industry overall. However, recent years have seen a slight plateau, driven in part by a decline in new FDA drug approvals. Despite this, emerging therapies, biosimilars, and the ongoing demand for biologics continue to fuel the growth of the pharmaceutical cold chain.
  • In particular, the introduction of biosimilars, such as those targeting Humira (adalimumab), a blockbuster biologic, has opened up new opportunities for the cold chain logistics market. As more biologics face competition from biosimilars, the logistics industry is poised to meet the growing demand for temperature-controlled shipping, ensuring that these products are delivered safely and efficiently.
  • Another key trend influencing the future of the pharmaceutical cold chain is the increasing reliance on home delivery services for healthcare and pharmaceuticals. Companies like UPS Healthcare are expanding their offerings in home delivery, a trend accelerated by the COVID-19 pandemic. With the continued growth of e-commerce and home-based healthcare, the demand for cold chain logistics in home delivery will continue to rise, presenting new challenges and opportunities for logistics providers.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global pharmaceutical cold chain logistics market report delivers a detailed analysis with 62 key tables, more than 52 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Service Type
  • 2.5. Snippet by Temperature Range
  • 2.6. Snippet by Mode of Delivery
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Cold Chain Technology
      • 3.1.1.2. Virtual Control Towers and Real-Time Tracking
    • 3.1.2. Restraints
      • 3.1.2.1. Regulatory Challenges
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Pharmaceutical Cold Chain Logistics Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Vaccines*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Biopharmaceuticals
  • 5.4. Drugs and Medicines

6. Pharmaceutical Cold Chain Logistics Market, By Service Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 6.1.2. Market Attractiveness Index, By Service Type
  • 6.2. Storage*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Transportation
  • 6.4. Packaging
  • 6.5. Others

7. Pharmaceutical Cold Chain Logistics Market, By Temperature Range

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 7.1.2. Market Attractiveness Index, By Temperature Range
  • 7.2. Frozen (Below -20°C) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Refrigerated (2°C to 8°C)
  • 7.4. Ambient (15°C to 25°C)
  • 7.5. Cryogenic (-150°C)

8. Pharmaceutical Cold Chain Logistics Market, By Mode of Delivery

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 8.1.2. Market Attractiveness Index, By Mode of Delivery
  • 8.2. Last-Mile Delivery *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Hubs-to-Distributor

9. Pharmaceutical Cold Chain Logistics Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Pharmaceutical and Biopharmaceutical Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Biotechnology Companies
  • 9.4. Hospitals and Healthcare Facilities
  • 9.5. Others

10. Pharmaceutical Cold Chain Logistics Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. Cardinal Health*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. AmerisourceBergen Corporation
  • 12.3. Envirotainer AB
  • 12.4. FedEx
  • 12.5. United Parcel Service of America, Inc.
  • 12.6. Thermo King
  • 12.7. Sonoco ThermoSafe
  • 12.8. B Medical Systems India Private Limited
  • 12.9. DoKaSch TEMPERATURE SOLUTIONS GmbH
  • 12.10. Nordic Cold Chain Solutions

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us